- Home
- REAX vs ANAB Comparison
REAX vs ANAB Comparison
Compare REAX & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REAX
- ANAB
- Stock Information
- Founded
- REAX 2018
- ANAB 2005
- Country
- REAX United States
- ANAB United States
- Employees
- REAX N/A
- ANAB N/A
- Industry
- REAX
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- REAX
- ANAB Health Care
- Exchange
- REAX Nasdaq
- ANAB Nasdaq
- Market Cap
- REAX 909.7M
- ANAB 759.5M
- IPO Year
- REAX N/A
- ANAB 2017
- Fundamental
- Price
- REAX $4.12
- ANAB $19.20
- Analyst Decision
- REAX Strong Buy
- ANAB Buy
- Analyst Count
- REAX 2
- ANAB 10
- Target Price
- REAX $6.00
- ANAB $36.38
- AVG Volume (30 Days)
- REAX 816.2K
- ANAB 917.7K
- Earning Date
- REAX 03-06-2025
- ANAB 05-08-2025
- Dividend Yield
- REAX N/A
- ANAB N/A
- EPS Growth
- REAX N/A
- ANAB N/A
- EPS
- REAX N/A
- ANAB N/A
- Revenue
- REAX $1,264,639,000.00
- ANAB $91,280,000.00
- Revenue This Year
- REAX $26.91
- ANAB N/A
- Revenue Next Year
- REAX $19.13
- ANAB $70.85
- P/E Ratio
- REAX N/A
- ANAB N/A
- Revenue Growth
- REAX 83.50
- ANAB 432.03
- 52 Week Low
- REAX $3.02
- ANAB $12.21
- 52 Week High
- REAX $6.75
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- REAX 38.15
- ANAB 60.03
- Support Level
- REAX $3.97
- ANAB $17.35
- Resistance Level
- REAX $4.25
- ANAB $19.82
- Average True Range (ATR)
- REAX 0.20
- ANAB 1.41
- MACD
- REAX -0.01
- ANAB 0.16
- Stochastic Oscillator
- REAX 28.48
- ANAB 71.76
About REAX The Real Brokerage Inc.
The Real Brokerage Inc is a technology-powered real estate brokerage firm located in the United States and Canada. It has developed a proprietary transaction management and brokerage operations software called reZEN, which powers nearly all of its brokerage operations, enabling efficiency, automation, and flexibility by incorporating end-to-end transaction management, automated compliance and brokerage oversight, integrated payments and financial services, Leo CoPilot, and open API for customization. In addition, the company also offers mortgage brokering and title services. The company's operating segments are North American Brokerage, which derives key revenue, One Real Title, One Real Mortgage, and Real Wallet. Geographically, it derives key revenue from the United States.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).